Impact of Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status

Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Kyohei Yugawa, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshiyuki Kitamura, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Shingo Baba, Kousei Ishigami, Yoshinao Oda, Masaki Mori – 22 October 2021 – We examined phosphorylated nuclear factor erythroid 2–related factor 2 (P‐NRF2) expression in surgically resected primary hepatocellular carcinoma (HCC) and investigated the association of P‐NRF2 expression with clinicopathological features and patient outcome.

Liver Disease and Risk of Hepatocellular Carcinoma in Children With Mutations in TALDO1

Tassos Grammatikopoulos, Nedim Hadzic, Pierre Foskett, Sandra Strautnieks, Marianne Samyn, Roshni Vara, Anil Dhawan, Jozef Hertecant, Fatma Al Jasmi, Obydur Rahman, University of Washington Center for Mendelian Genomics, Maesha Deheragoda, Laura N. Bull, Richard J Thompson – 21 October 2021 – Mutations in the transaldolase 1 (TALDO1) gene have been described in a limited number of cases. Several organs can be affected and clinical manifestations are variable, but often include liver dysfunction and/or hepatosplenomegaly.

Frailty and the Risk of Acute Kidney Injury Among Patients With Cirrhosis

Giuseppe Cullaro, Elizabeth C. Verna, Andres Duarte‐Rojo, Matthew R. Kappus, Daniel R. Ganger, Robert S. Rahimi, Brian Boyarsky, Dorry L. Segev, Mara McAdams‐DeMarco, Daniela P. Ladner, Michael L. Volk, Chi‐yuan Hsu, Jennifer C. Lai – 21 October 2021 – Acute kidney injury (AKI) and frailty are major drivers of outcomes among patients with cirrhosis. What is unknown is the impact of physical frailty on the development of AKI. We included adults with cirrhosis without hepatocellular carcinoma listed for liver transplantation at nine US centers (n = 1,033).

Traf2 and NCK Interacting Kinase Is a Critical Regulator of Procollagen I Trafficking and Hepatic Fibrogenesis in Mice

Samuel C. Buchl, Zachary Hanquier, Andrew J. Haak, Yvonne M. Thomason, Robert C. Huebert, Vijay H. Shah, Jessica L. Maiers – 21 October 2021 – Hepatic fibrosis is driven by deposition of matrix proteins following liver injury. Hepatic stellate cells (HSCs) drive fibrogenesis, producing matrix proteins, including procollagen I, which matures into collagen I following secretion. Disrupting intracellular procollagen processing and trafficking causes endoplasmic reticulum stress and stress‐induced HSC apoptosis and thus is an attractive antifibrotic strategy.

Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus

Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Kouji Joko, Takehiro Akahane, Koichiro Furuta, Haruhiko Kobashi, Hiroyuki Kimura, Hitoshi Yagisawa, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Hideo Yoshida, Yasushi Uchida, Toshifumi Tada, Shinichiro Nakamura, Satoshi Yasuda, Hidenori Toyoda, Rohit Loomba, Namiki Izumi – 21 October 2021 – The identification of patients with advanced fibrosis who do not need any further hepatocellular carcinoma (HCC) surveillance after the eradication of hepatitis C is pivotal.

Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Marica Meroni, Miriam Longo, Rosa Lombardi, Erika Paolini, Chiara Macchi, Alberto Corsini, Cesare R. Sirtori, Anna Ludovica Fracanzani, Massimiliano Ruscica, Paola Dongiovanni – 21 October 2021 – Dyslipidemia and cardiovascular complications are comorbidities of nonalcoholic fatty liver disease (NAFLD), which ranges from simple steatosis to nonalcoholic steatohepatitis, fibrosis, and cirrhosis up to hepatocellular carcinoma.

Subscribe to